

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SciClone Pharmaceuticals (Holdings) Limited

賽生藥業控股有限公司 *

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6600)

**CHANGE OF VENUE OF
THE ANNUAL GENERAL MEETING
TO BE HELD ON MAY 19, 2022**

References are made to (i) the circular of SciClone Pharmaceuticals (Holdings) Limited (the “**Company**”) dated April 14, 2022 (the “**Circular**”); (ii) the notice of the annual general meeting (the “**AGM**”) of the Company dated April 14, 2022 (the “**Notice of AGM**”); and (iii) the form of proxy in relation to the AGM to be held on Thursday, May 19, 2022 at 3:00 p.m. (the “**Proxy Form**”). Unless otherwise specified, capitalised terms used herein have the same meanings as those defined in the Circular.

The Board hereby announces that in view of the recent quarantine measures in Shanghai, the PRC, for prevention and control of COVID-19 pandemic, the venue of the AGM is now changed to the Company’s office in Hong Kong at Room 3401A, Windsor House, 311 Gloucester Road, Causeway Bay, Hong Kong.

Apart from the change of venue of the AGM, all the information set forth in the Circular, the Notice of AGM and the Proxy Form, including, among others, the date and time of the AGM, the book closure period for the register of members and the resolutions to be considered at the AGM, remains unchanged. For the avoidance of doubt, any Proxy Form duly completed and returned in accordance with the instructions printed thereon remains valid for the AGM, and the shareholders of the Company (“**Shareholders**”) are not required to resubmit the Proxy Form if they have already done so.

Shareholders who intend to attend the AGM are advised to pay attention to the change of venue of the AGM as stated above.

By order of the Board
SciClone Pharmaceuticals (Holdings) Limited
PAN Rongrong
Chief Financial Officer and Joint Company Secretary

Hong Kong, May 10, 2022

As at the date of this announcement, the Board comprises Mr. Zhao Hong as executive director, Mr. Li Zhenfu, Dr. Daniel Luzius Vasella, Ms. Lin Shirley Yi-Hsien, Ms. Li Quan, Mr. Shi Cen and Ms. Wang Haixia as non-executive directors, and Dr. Liu Guoen, Dr. Chen Ping, Mr. Gu Alex Yushao and Ms. Wendy Hayes as independent non-executive directors.

* for identification purpose only